REAADS PROTEIN C ANTIGEN TEST KIT by REAADS MEDICAL PRODUCTS, INC.

The REAADS Protein C Antigen Test Kit is an in vitro diagnostic assay for the quantitative determination of plasma levels of human Protein C (as a percent of normal concentration) by enzyme linked immunosorbent assay (ELISA). Plasma levels of Protein C may be used in conjunction with other assays as an aid in diagnosing congenital or acquired Protein C deficiencies associated with thrombotic disease.

Device Description

The REAADS Protein C Antigen Test Kit is a sandwich enzyme linked immunosorbent assay (ELISA). The capture antibody specific for human Protein C is coated to 96 microwell polystyrene plate. Diluted patient plasma is incubated in the wells, allowing any available Protein C to bind to the anti-human Protein C antibody bound to the plastic. The plates are washed to remove any unbound Protein C or other plasma molecules. Bound Protein C is quantitated using an HRP conjugated anti-human Protein C detection antibody. Any unbound conjugated anti-human Protein C is washed away after an incubation period. A chromogenic substrate of tetramethylbenzidine (TMB) and hydrogen peroxide (H2O2) is added to develop a colored reaction. The intensity of the color is measured spectrophotometrically at 450nm in optical density (O.D.) units. Protein C Antigen relative percent concentrations in patient plasma is determined against a curve made from a reference plasma.

AI/ML Overview

The provided text describes the REAADS Protein C Antigen Test Kit, an in vitro diagnostic assay. Here's a breakdown of the acceptance criteria and the study that proves the device meets those criteria, based on the provided information:

Acceptance Criteria and Study Details for REAADS Protein C Antigen Test Kit

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria	Reported Device Performance
Substantial equivalence to a legally marketed predicate device (Helena Protein C Antigen Rocket EID Method).	Coefficient of correlation (r) for the entire population = 0.949
	P-value (by single factor ANOVA) = 0.838
Statistical similarity of results between the two methods.	The reported r-value and p-value indicate statistical similarity, with the P-value being well above common significance thresholds (e.g., 0.05).
Performance comparability.	"in general the performance was comparable"

2. Sample Size and Data Provenance

Test Set Sample Size: Not explicitly stated. The text mentions "Test results for clinical samples" and "the entire population" for the correlation analysis, but does not provide a specific number of samples.
Data Provenance: Not explicitly stated regarding country of origin or whether it was retrospective or prospective. It refers to "patient plasma" and "clinical samples," suggesting human samples.

3. Number and Qualifications of Experts for Ground Truth

Not applicable for this type of device. This device is an in vitro diagnostic assay that measures Protein C antigen levels. The "ground truth" for its performance is typically established by comparing its quantitative measurements to a reference method or a validated predicate device, not by expert consensus on interpretations.

4. Adjudication Method

Not applicable. See explanation above. The performance evaluation relies on quantitative comparison between assays, not subjective interpretation requiring adjudication.

5. Multi Reader Multi Case (MRMC) Comparative Effectiveness Study

No. This is not an imaging or diagnostic interpretation device where human readers are involved in the direct output that is being compared. The study compares the quantitative results of two laboratory tests.

6. Standalone Performance Study

Yes, a standalone comparison was performed. The study directly compares the quantitative results of the REAADS Protein C Antigen Test Kit (algorithm only, as it's an ELISA test) to a predicate device (Helena Protein C Antigen Rocket EID Method). The results reported (r=0.949, p=0.838) are indicative of the device's standalone performance compared to the predicate.

7. Type of Ground Truth Used

Comparison to a Legally Marketed Predicate Device. The "ground truth" or reference standard for this substantial equivalence claim is the performance of the Helena Protein C Antigen Rocket EID Method. The study directly compares the REAADS kit's results to those obtained using the Helena method.

8. Sample Size for the Training Set

Not applicable. This device is a quantitative assay, not a machine learning model that requires a "training set" in the typical sense. Product development for such assays involves internal validation and optimization, but the term "training set" is not relevant here.

9. How the Ground Truth for the Training Set was Established

Not applicable. As a quantitative assay, there is no "training set" for ground truth in the machine learning context. The assay's analytical performance (e.g., sensitivity, specificity, accuracy, precision) is established through laboratory experiments and comparison to established methods or reference materials.

Summary

{0}------------------------------------------------

SUMMARY OF 510(K) SAFETY AND EFFECTIVENESS

REAADS Protein C Antigen Test Kit

June 20, 1997

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The REAADS Protein C Antigen Test Kit is compared to a legally marketed predicate device and a substantial equivalence claim is made. The predicate device is the Helena Protein C Antigen Rocket EID Method, currently manufactured and marketed by Helena Laboratories, Beaumont, Texas.

The intended use of the device is to quantitatively determine Protein C levels (relative to percent of normal concentration) in human plasma. Normal levels of Protein C are generally accepted to be between 65-150% as compared to a standard or pooled normal plasma. A decreased Protein C activity in plasma may be the result of low concentrations and function (type I) or only low function (type II). The laboratory diagnosis of Protein C deficiency may require both quantitative and qualitiative (functional) determinations.

Test results for clinical samples demonstrate that the performance of the REAADS Protein C Antigen Test Kit and the Helena Protein C Antigen Rocket EID Method is substantially equivalent. The coefficient of correlation (r) for the entire population is 0.949, with a P-value of 0.838 (by single factor ANOVA), indicating the results by the two methods are statistically similar. Although a few minor differences in value recovery were observed between the assays, in general the performance was comparable. The differences may be attributed to the improved specificity of REAADS ELISA technology when compared to EID.

Nance Dertle

06/20/97
Date

Nanci Dexter Director, Quality and Regulatory Affairs

{1}------------------------------------------------

Image /page/1/Picture/2 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized design of three human profiles facing to the right, stacked slightly on top of each other. The profiles are simple and abstract, with no facial details. The logo is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" in a circular arrangement.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Ms. Nanci Dexter Director, Quality and Requlatory Affairs REAADS MEDICAL PRODUCTS, INC. 12061 Tejon Street Westminster, Colorado 80234

OCT - 6 1997

Re: K972342 Trade Name: REAADS Protein C Antigen Test Kit Requlatory Class: II Product Code: GGP Dated: July 30, 1997 Received: August 1, 1997

Dear Ms. Dexter:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Druq, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.

{2}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven Putman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Indications for Use Statement

1972342 510(k) Number: _

Device Name: REAADS Protein C Antigen Test Kit

Indications for Use:

The REAADS Protein C Antigen Test Kit is intended to be used by clinical (hospital and reference) laboratories.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Atter E. Machin

(Division Sign-Off) Division of Clinical Laboratory Device 510(k) Number

Prescription
USE

Regulation Number and Section

§ 864.7290 Factor deficiency test.

(a)
Identification. A factor deficiency test is a device used to diagnose specific coagulation defects, to monitor certain types of therapy, to detect coagulation inhibitors, and to detect a carrier state (a person carrying both a recessive gene for a coagulation factor deficiency such as hemophilia and the corresponding normal gene).(b)
Classification. Class II (performance standards).